Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.

Radiat Oncol · 2022 · PMC9188229 · PMID 35690773

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

However, the OS difference did not achieve significance among patients with BCLC stage C or MVI, which may be explained by the shorter follow-up time for the PD1 + RT group.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.